The Impact of Surgical Intervention on The Survival of Primary Head and Neck MALT Lymphoma [0.03%]
手术干预对原发性头颈部MALT淋巴瘤患者生存影响的研究
Jianhong Zhang,Shan Liu
Jianhong Zhang
Background Primary head and neck mucosa-associated lymphoid tissue lymphoma (HN-MALT) is a rare B-cell lymphoma whose epidemiology, clinical features, and treatment strategies remain unclear. Methods We conducted a retrospective analysis of...
HBV integration in clinical management of hepatocellular carcinoma by liquid biopsy [0.03%]
基于液体活检的乙型肝炎病毒整合位点在肝细胞癌临床诊疗中的应用价值研究
Xueying Lyu,Zita Hoi-Ying Chan,Daniel Wai-Hung Ho
Xueying Lyu
Hepatitis B virus (HBV) infection is a significant risk factor for hepatocellular carcinoma (HCC). During the infection, HBV DNA integrates into the host genome, promoting hepatocarcinogenesis through both gene-dependent and gene-independen...
Review
Oncology. 2026 Mar 2:1-18. DOI:10.1159/000551214 2026
Weight variations during first-line systemic treatment of metastatic Non-Small Cell Lung Cancer: new paradigms from Real-World Data [0.03%]
转移性非小细胞肺癌一线全身治疗期间的体重变化：真实世界数据带来的新观念
Alexandre Gravian,Arnaud Pagès,Anthony Tarabay et al.
Alexandre Gravian et al.
Purpose In studies, weight loss is strongly associated with outcomes in metastatic non-squamous cell lung cancer (mNSCLC). This work examines weight variations in first-line treatment, exploring their mechanisms based on treatment type, age...
Prognostic effect of preoperative albumin-to-globulin ratio in patients with non-metastatic bladder cancer undergoing radical cystectomy [0.03%]
术前血清白蛋白/球蛋白比值对非转移性膀胱癌根治术患者预后的影响研究
Haruko Takada,Masaomi Ikeda,Rena Tanaka et al.
Haruko Takada et al.
Introduction: Blood-based inflammatory and nutritional biomarkers have been crucial prognostic indicators in various malignancies. This study aimed to investigate the association of preoperative biomarkers with postoperat...
Sustained Virologic Response and Prognosis in HCV-related Hepatocellular Carcinoma: Lessons from Complementary Cohorts [0.03%]
持续病毒学应答与丙型肝炎相关肝细胞癌的预后：来自互补队列的经验教训
Edoardo G Giannini,Sara Labanca,Simona Marenco et al.
Edoardo G Giannini et al.
The anti-apoptotic protein lifeguard is expressed in osteosarcoma, chondrosarcoma and soft tissue sarcoma [0.03%]
抗凋亡蛋白LIFR-GARD在骨肉瘤、软组织肉瘤和滑膜肉瘤中的表达
Sebastian Senger,Frederik Schlottmann,Sarah Strauß et al.
Sebastian Senger et al.
The success of modern chemotherapy in overall survival of patients with advanced stages of osteosarcoma and soft tissue sarcoma has reached a plateau. Therefore a deeper understanding of molecular mechanisms behind deregulated apoptosis in ...
In the article "Prognostic Factors in Pleural Mesothelioma Patients Receiving First-Line Chemotherapy: Establishing the PLECH Baseline Risk Score" [Oncology. 2025;103:1088-1096; https://doi.org/10.1159/000543637] by Guijosa et al., the foll...
Published Erratum
Oncology. 2026 Feb 2:1. DOI:10.1159/000550028 2026
Significance of Measuring Interferon-γ-Induced Protein-10 Levels in Patients Receiving Systemic Therapies for Unresectable Hepatocellular Carcinoma [0.03%]
系统治疗不可切除肝细胞癌患者干扰素γ诱导蛋白10水平检测的意义分析
Hitomi Takada,Leona Osawa,Yasuyuki Komiyama et al.
Hitomi Takada et al.
Introduction: Atezolizumab-bevacizumab (AB) and durvalumab-tremelimumab (DT) combination therapies are widely used for the treatment of unresectable hepatocellular carcinoma (u-HCC). However, the optimal predictors of the...
Evaluating the Safety of Combining Tyrosine Kinase Inhibitors with Anticoagulants in Chronic Myeloid Leukemia: A Systematic Review [0.03%]
酪氨酸激酶抑制剂与抗凝药物联用治疗慢性髓性白血病的安全性评估：系统综述
Amna Gameil,Rola Ghasoub,Neda Jafari et al.
Amna Gameil et al.
Introduction: The prognosis of chronic myeloid leukemia (CML) has been revolutionized in recent decades with tyrosine kinase inhibitors (TKIs). Yet, comorbidities that require anticoagulation therapy pose a challenge in C...
Multicenter Study on the Safety and Efficacy of First-Line Nivolumab-Combination Chemotherapy in Patients Aged 75 years and Older with Unresectable Advanced or Recurrent Gastric Cancer [0.03%]
一项多中心研究：一线使用纳武利尤单抗联合化疗治疗不可切除的局部晚期或转移性胃癌75岁及以上患者的安全性和疗效研究
Akiharu Kimura,Akihiko Sano,Nobuhiro Nakazawa et al.
Akiharu Kimura et al.
Introduction: Nivolumab combined with chemotherapy has been approved as the first-line treatment for HER2-negative, unresectable, advanced, or recurrent gastric cancer. Patients aged ≥ 75 years more often have impaired o...